Prescient Medical's Dual Approach to Vulnerable Plaque
Executive Summary
Vulnerable plaque caught investors' and entrepreneurs' attention several years ago as the mysterious cause of more than half of all cases of sudden cardiac death, most of which occurs in people with no history of heart disease. Several companies were launched and much money invested with little to show for it. One major problem: vulnerable plaque requires new tools both to diagnose and treat the condition, which proved to be bigger hurdles than most start-ups can overcome. Prescient was launched by an experienced device management team and is applying Raman spectroscopy, to coronary disease as the basis of its diagnostic tool, and is using a shield-not a stent-for its therapeutic device.
You may also be interested in...
Creating J&J's Cardiology Franchise: An Interview with Marv Woodall
In this interview, Marv Woodall, the architect of Johnson & Johnson's cardiology business, reflects on the ups and downs of building a stent business, integrating a hostile takeover, and why--despite all their success--stents have not met their original goal.
Creating J&J's Cardiology Franchise: An Interview with Marv Woodall
In this interview, Marv Woodall, the architect of Johnson & Johnson's cardiology business, reflects on the ups and downs of building a stent business, integrating a hostile takeover, and why--despite all their success--stents have not met their original goal.
InfraReDx: Saved by Angels (and a VC)
A rare combination of angels and the sole interested VC brought InfraReDx back from failure's door in search of a new way to identify the biggest mystery behind heart attacks--vulnerable plaque.